Is ENTA or ERAS more undervalued in 2026?

CirclFi compares Enanta Pharmaceuticals, Inc. (ENTA) and Erasca, Inc. (ERAS) using 13 institutional-grade valuation models. ENTA has a Quality of Company score of 5.1/10 while ERAS scores 4.2/10.

Which is a better buy — ENTA or ERAS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ENTA and ERAS valuations compare?

ENTA at $13.23 and ERAS at $12.20 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ENTA vs ERAS Valuation Comparison 2026 — Intrinsic Value Analysis

ENTA

Biotechnology

Enanta Pharmaceuticals, Inc.

Quality

5.1

out of 10

Value Trap

LOW

Price

$13.23

Last close

Models

10/13

Active

ERAS

Biotechnology

Erasca, Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$12.20

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	ENTA Fair Value	ENTA Upside	ERAS Fair Value	ERAS Upside
Bayesian DCF	Intrinsic	$2.32	-82.5%	$3.70	-69.7%
Earnings Power Value	Intrinsic	—	—	$9.40	-56.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.03	-92.5%	$0.94	-90.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENTA vs ERAS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENTA vs ERAS — Which Stock Is More Undervalued?

ENTA scores higher with a 5.1/10 quality rating vs ERAS's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Enanta Pharmaceuticals, Inc. (ENTA) and Erasca, Inc. (ERAS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENTA currently trades at $13.23 with a QOC of 5.1/10, while ERAS trades at $12.20 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).